hyFc or hybrid Fc platform is our own proprietary technology designed to drive
the discovery of a wide range of differentiated agonistic protein therapeutics.
Based on one of leading long-acting technologies, Fc fusion, hyFc is designed to overcome the shortcomings of conventional IgG1-based Fc fusion proteins such as inflexible hinge which limits applicability and side-effects due to antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). hyFc is derived from hybridization of non-cytosolic immunoglobulin Fc portions of IgD and IgG4 without site-directed mutagenesis. This hybridization combination gives flexible hinge that minimizes the loss of bioactivity of drug candidate and prevents adverse immunogenicity and cleavage by enzymes. hyFc thus has broad applicability, less side-effects and superior long-acting characteristics to the drug candidates.
hyFc is a platform technology constructed to produce long-acting Fc fusion proteins by hybridizing IgD and IgG4
|Human Ig Isotypes||lgG1||lgG4||lgD|
|Binding of FcyR of
|Activation of C1q (CDC)||++||-||-|
|Binding of FcRn||++++||++++||-|
|In vivo serum
Genexine's hyFc technology can be applied to a broad range of drug moieties including small peptides and proteolytic enzymes. Genexine has a number of highly differentiated hyFc-based product candidates at various stages of development in its pipeline. We also have a undisclosed partnerships on hyFc product candidates with leading biopharmaceutical companies.
and low immunogenic risk
than glycosylated products
Applicable to cytokines, hormones,
small peptides and Fab antibody